|
|
||||||||
From the Department of Neurology (D.M.W.), Mayo Clinic College of Medicine, Scottsdale, AZ; and Departments of Neurology (S.J.P., C.F.L., V.A.L., B.G.W.), Laboratory Medicine and Pathology (V.A.L., S.J.P.), and Immunology (V.A.L.), Mayo Clinic College of Medicine, Rochester, MN.
Address correspondence and reprint requests to Dr. Dean M. Wingerchuk, Department of Neurology, Mayo Clinic College of Medicine, 13400 East Shea Boulevard, Scottsdale, AZ 85259; e-mail: wingerchuk.dean{at}mayo.edu
We compared the clinical course of 96 patients with neuromyelitis optica (NMO) to multiple sclerosis (MS) natural history data. Based on the distribution of follow-up data (median 6.1 year), we estimated that 21 NMO patients would convert to a secondary progressive course, but we observed only two conversions (p = 0.00002; relative risk = 0.08). The disparate natural histories of MS and NMO suggest dissociation between relapses and clinical progression in CNS demyelinating diseases.
Disclosure: The authors report no conflicts of interest.
Received August 24, 2006. Accepted in final form October 23, 2006.
Related Article
Neurology 2007 68: 540-541.
This article has been cited by other articles:
![]() |
K. Yanagawa, I. Kawachi, Y. Toyoshima, A. Yokoseki, M. Arakawa, A. Hasegawa, T. Ito, N. Kojima, R. Koike, K. Tanaka, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis Neurology, November 17, 2009; 73(20): 1628 - 1637. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jacob, M. Matiello, B. G. Weinshenker, D. M. Wingerchuk, C. Lucchinetti, E. Shuster, J. Carter, B. M. Keegan, O. H. Kantarci, and S. J. Pittock Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients Arch Neurol, September 1, 2009; 66(9): 1128 - 1133. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. McKeon, J. P. Fryer, M. Apiwattanakul, V. A. Lennon, S. R. Hinson, T. J. Kryzer, C. F. Lucchinetti, B. G. Weinshenker, D. M. Wingerchuk, E. A. Shuster, et al. Diagnosis of Neuromyelitis Spectrum Disorders: Comparative Sensitivities and Specificities of Immunohistochemical and Immunoprecipitation Assays Arch Neurol, September 1, 2009; 66(9): 1134 - 1138. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nasir, D. A. Kerr, and J. Birnbaum Nineteen Episodes of Recurrent Myelitis in a Woman With Neuromyelitis Optica and Systemic Lupus Erythematosus Arch Neurol, September 1, 2009; 66(9): 1160 - 1163. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Hinson, A. McKeon, J. P. Fryer, M. Apiwattanakul, V. A. Lennon, and S. J. Pittock Prediction of Neuromyelitis Optica Attack Severity by Quantitation of Complement-Mediated Injury to Aquaporin-4-Expressing Cells Arch Neurol, September 1, 2009; 66(9): 1164 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Ratchford, M. E. Quigg, A. Conger, T. Frohman, E. Frohman, L. J. Balcer, P. A. Calabresi, and D. A. Kerr Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies Neurology, July 28, 2009; 73(4): 302 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Bichuetti, E. Oliveira, N. Souza, R. Rivero, and A. Gabbai Neuromyelitis optica in Brazil: a study on clinical and prognostic factors Multiple Sclerosis, May 1, 2009; 15(5): 613 - 619. [Abstract] [PDF] |
||||
![]() |
G. Giovannoni To test or not to test: NMO-IgG and optic neuritis Neurology, June 3, 2008; 70(23): 2192 - 2193. [Full Text] [PDF] |
||||
![]() |
C. C. Glisson and S. L. Galetta Is Neuromyelitis Optica Eyeing a Distinct Path From Multiple Sclerosis? Arch Ophthalmol, January 1, 2008; 126(1): 128 - 129. [Full Text] [PDF] |
||||
![]() |
B. Weinshenker, S. Galetta, J. Bennett, D. Kerr, and E. M. Frohman More on Multiple Sclerosis and Neuromyelitis Optica Reply Arch Neurol, December 1, 2007; 64(12): 1802 - 1803. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |